PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.

Abstract Nab-paclitaxel (nab-PTX) is an albumin-bound paclitaxel formulation. Although nab-PTX has shown superior efficacy compared to conventional paclitaxel (PTX) in metastatic breast cancer (MBC), chemotherapy-induced peripheral neuropathy (CIPN) was more frequently observed in nab-PTX. In this study, we aimed to estimate the feasibility of the nab-PTX 175 mg/m2/3weeks regimen.
PMID
Related Publications

Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.

Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.

Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer.

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.

Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.

Authors

Mayor MeshTerms
Keywords

HER2-negative breast cancer

Metastatic breast cancer

chemotherapy

nanoparticle albumin-bound paclitaxel

peripheral neuropathy

safety

Journal Title anticancer research
Publication Year Start 








































PMID- 29277798
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for
      HER2-negative Metastatic Breast Cancer.
PG  - 379-383
AB  - BACKGROUND/AIM: Nab-paclitaxel (nab-PTX) is an albumin-bound paclitaxel
      formulation. Although nab-PTX has shown superior efficacy compared to
      conventional paclitaxel (PTX) in metastatic breast cancer (MBC),
      chemotherapy-induced peripheral neuropathy (CIPN) was more frequently observed in
      nab-PTX. In this study, we aimed to estimate the feasibility of the nab-PTX 175
      mg/m(2)/3weeks regimen. PATIENTS AND METHODS: Patients having metastatic or
      inoperable HER2-negative breast cancer received 175 mg/m(2) of nab-PTX every
      three weeks. The primary endpoint was safety and the secondary endpoints were
      response and survival. RESULTS: Seventeen patients were enrolled with a median
      age of 64 years. Ten patients had estrogen receptor positive disease and seven
      had triple-negative disease. CIPN was observed in seven patients (41%) however,
      grade 3 CIPN was only seen in one patient (6%). Objective response rate was 41%
      and progression-free survival was 23 weeks. CONCLUSION: Nab-PTX 175 mg/m(2)/3wks 
      regimen has a good safety profile and less frequent CIPN. This regimen can
      contribute to the strategy of MBC treatment.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Takashima, Tsutomu
AU  - Takashima T
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan [email protected]
FAU - Kawajiri, Hidemi
AU  - Kawajiri H
AD  - Department of Breast Surgery, Ishikiri Seiki Hospital, Osaka, Japan.
FAU - Nishimori, Takeo
AU  - Nishimori T
AD  - Department of Surgery, Ikuwakai Memorial Hospital, Osaka, Japan.
FAU - Tei, Seika
AU  - Tei S
AD  - Department of Surgery, Seichokai Fuchu Hospital, Osaka, Japan.
FAU - Nishimura, Shigehiko
AU  - Nishimura S
AD  - Department of Surgery, Sumitomo Hospital, Osaka, Japan.
FAU - Yamagata, Shigehito
AU  - Yamagata S
AD  - Department of Surgery, Seichokai Fuchu Hospital, Osaka, Japan.
FAU - Tokunaga, Shinya
AU  - Tokunaga S
AD  - Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan.
FAU - Mizuyama, Yoko
AU  - Mizuyama Y
AD  - Department of Surgery, Ohno Memorial Hospital, Osaka, Japan.
FAU - Sunami, Takeshi
AU  - Sunami T
AD  - Department of Surgery, Izumi Municipal Hospital, Osaka, Japan.
FAU - Tezuka, Kenji
AU  - Tezuka K
AD  - Department of Surgery, Kishiwada City Hospital, Osaka, Japan.
FAU - Ikeda, Katsumi
AU  - Ikeda K
AD  - Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan.
AD  - Department of Breast Surgery, Osaka City General Hospital, Osaka, Japan.
FAU - Ogawa, Yoshinari
AU  - Ogawa Y
AD  - Department of Breast Surgery, Osaka City General Hospital, Osaka, Japan.
FAU - Kashiwagi, Shinichiro
AU  - Kashiwagi S
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Noda, Satoru
AU  - Noda S
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Onoda, Naoyoshi
AU  - Onoda N
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Ishikawa, Tetsuro
AU  - Ishikawa T
AD  - Department of Surgery, Kashiwara Municipal Hospital, Osaka, Japan.
FAU - Kudoh, Shinzoh
AU  - Kudoh S
AD  - Department of Internal Medicine, Osaka Socio-Medical Center Hospital, Osaka,
      Japan.
FAU - Takada, Minoru
AU  - Takada M
AD  - Hanwa Daini Senboku Hospital, Osaka, Japan.
FAU - Hirakawa, Kosei
AU  - Hirakawa K
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Ohira, Masaichi
AU  - Ohira M
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - HER2-negative breast cancer
OT  - Metastatic breast cancer
OT  - chemotherapy
OT  - nanoparticle albumin-bound paclitaxel
OT  - peripheral neuropathy
OT  - safety
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2017/11/03 00:00 [revised]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/379 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):379-383.